Mgr. Václav Šeda, Ph.D.
Junior researcher, Marek Mráz Research Group
Office: bldg. E35/281
Kamenice 753/5
625 00 Brno
Phone: | +420 549 49 7500 |
---|---|
E‑mail: |
Total number of publications: 81
2018
-
Inovativní inhibitor proteinu CHK1 indukuje apoptózu u buněk chronické lymfocytární leukémie s mutacemi v genu TP53
Year: 2018, type: Conference abstract
-
miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels
Blood, year: 2018, volume: 132, edition: 22, DOI
-
MYC-mediated downregulation of miR-150 contributes to the transformation of follicular lymphoma by upregulating FOXP1 levels
Year: 2018, type: Conference abstract
-
MYC-mediated downregulation of miR-150 contributes to the transformation of follicular lymphoma to DLBCL by upregulating FOXP1 levels
Year: 2018, type: Conference abstract
-
Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels
Leukemia, year: 2018, volume: 32, edition: 9, DOI
-
Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations
Year: 2018, type: Conference abstract
2017
-
BCR signalling proficient chronic lymphocytic leukaemia cells are prone to rituximab mediated elimination in vivo.
Year: 2017, type: Conference abstract
-
Differential expression of microRNAs in transformation of follicular lymphoma to diffuse large B cell lymphoma
Year: 2017, type: Conference abstract
-
Down-regulation of miR-150 and up-regulation of its target FOXP1 is associated with transformation of follicular lymphoma.
Year: 2017, type: Conference abstract
-
MicroRNA induced by DNA damage response regulate the expression of FOXP1 and therapy response in CLL
Year: 2017, type: Conference abstract